CO2023011154A2 - Composiciones y métodos para tratar angioedema hereditario - Google Patents
Composiciones y métodos para tratar angioedema hereditarioInfo
- Publication number
- CO2023011154A2 CO2023011154A2 CONC2023/0011154A CO2023011154A CO2023011154A2 CO 2023011154 A2 CO2023011154 A2 CO 2023011154A2 CO 2023011154 A CO2023011154 A CO 2023011154A CO 2023011154 A2 CO2023011154 A2 CO 2023011154A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compositions
- hereditary angioedema
- nucleic acids
- treating hereditary
- Prior art date
Links
- 206010019860 Hereditary angioedema Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000055157 Complement C1 Inhibitor Human genes 0.000 abstract 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142121P | 2021-01-27 | 2021-01-27 | |
| US202163201466P | 2021-04-30 | 2021-04-30 | |
| US202163261603P | 2021-09-24 | 2021-09-24 | |
| PCT/US2022/014091 WO2022165027A2 (en) | 2021-01-27 | 2022-01-27 | Compositions and methods for treating hereditary angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023011154A2 true CO2023011154A2 (es) | 2023-09-08 |
Family
ID=82653909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0011154A CO2023011154A2 (es) | 2021-01-27 | 2023-08-25 | Composiciones y métodos para tratar angioedema hereditario |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240110201A1 (https=) |
| EP (1) | EP4284417A4 (https=) |
| JP (1) | JP2024506266A (https=) |
| KR (1) | KR20230136147A (https=) |
| AU (1) | AU2022214192A1 (https=) |
| CA (1) | CA3207268A1 (https=) |
| CL (1) | CL2023002138A1 (https=) |
| CO (1) | CO2023011154A2 (https=) |
| IL (1) | IL304404A (https=) |
| MX (1) | MX2023008801A (https=) |
| PE (1) | PE20240692A1 (https=) |
| WO (1) | WO2022165027A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240408240A1 (en) * | 2021-10-01 | 2024-12-12 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations |
| CN117947040A (zh) * | 2022-10-31 | 2024-04-30 | 苏州荷光科汇生物科技有限公司 | 用于目的基因的表达盒及其应用 |
| AU2024257493A1 (en) * | 2023-04-18 | 2025-12-04 | Siren Biotechnology, Inc. | Adeno-associated viral vector compositions and methods of use |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101610268B1 (ko) * | 2007-08-28 | 2016-04-07 | 애들레이드 리서치 앤드 이노베이션 피티와이 리미티드 | 외과용 하이드로겔 |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| CN108064176A (zh) * | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| US10214731B2 (en) * | 2015-05-28 | 2019-02-26 | Cornell University | Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema |
| WO2021081280A1 (en) * | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| JP2023503850A (ja) * | 2019-11-14 | 2023-02-01 | バイオマリン ファーマシューティカル インコーポレイテッド | 肝臓特異的遺伝子療法ベクターによる遺伝性血管浮腫の治療 |
-
2022
- 2022-01-27 CA CA3207268A patent/CA3207268A1/en active Pending
- 2022-01-27 JP JP2023545212A patent/JP2024506266A/ja not_active Withdrawn
- 2022-01-27 AU AU2022214192A patent/AU2022214192A1/en not_active Abandoned
- 2022-01-27 PE PE2023002174A patent/PE20240692A1/es unknown
- 2022-01-27 WO PCT/US2022/014091 patent/WO2022165027A2/en not_active Ceased
- 2022-01-27 EP EP22746602.6A patent/EP4284417A4/en not_active Withdrawn
- 2022-01-27 MX MX2023008801A patent/MX2023008801A/es unknown
- 2022-01-27 KR KR1020237028214A patent/KR20230136147A/ko active Pending
- 2022-01-27 US US18/262,959 patent/US20240110201A1/en active Pending
-
2023
- 2023-07-11 IL IL304404A patent/IL304404A/en unknown
- 2023-07-21 CL CL2023002138A patent/CL2023002138A1/es unknown
- 2023-08-25 CO CONC2023/0011154A patent/CO2023011154A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023008801A (es) | 2023-09-22 |
| WO2022165027A3 (en) | 2022-09-09 |
| EP4284417A2 (en) | 2023-12-06 |
| WO2022165027A2 (en) | 2022-08-04 |
| CL2023002138A1 (es) | 2024-04-19 |
| US20240110201A1 (en) | 2024-04-04 |
| CA3207268A1 (en) | 2022-08-04 |
| AU2022214192A9 (en) | 2023-08-24 |
| KR20230136147A (ko) | 2023-09-26 |
| JP2024506266A (ja) | 2024-02-13 |
| AU2022214192A1 (en) | 2023-07-27 |
| EP4284417A4 (en) | 2024-12-25 |
| IL304404A (en) | 2023-09-01 |
| PE20240692A1 (es) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023011154A2 (es) | Composiciones y métodos para tratar angioedema hereditario | |
| CL2020002973A1 (es) | Casetes de expresión de a- glucosidasa de ácido optimizado con codón y métodos de uso del mismo | |
| CL2020001133A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664) | |
| CO2022003582A2 (es) | Métodos para el tratamiento de la oftalmopatía tiroidea | |
| CO2019011543A2 (es) | Inhibidores de pd-1/pd-l1 | |
| MX2020013236A (es) | Acido ribonucleico (arn) circular para traduccion en celulas eucariotas. | |
| CO2023010599A2 (es) | Composiciones y métodos para tratar la enfermedad de fabry | |
| BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
| CL2018001198A1 (es) | Métodos y composiciones para edición génica en hemocitoblastos | |
| UY31724A (es) | " compuestos heterocíclicos novedosos y usos de los mismos" | |
| MX2021000328A (es) | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. | |
| BR112022021562A2 (pt) | Partículas interferentes terapêuticas para o coronavírus | |
| BR112021021149A2 (pt) | Métodos e composições para a geração de alelos dominantes utilizando a edição de genomas | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| CO2024005281A2 (es) | Composiciones y métodos para expresar el factor ix para terapia para la hemofilia b | |
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| BR112021026326A2 (pt) | Sacarose fosforilase engenheirada, composição, sequência de polinucleotídeo, vetor de expressão, célula hospedeira, e, método para produzir uma sacarose fosforilase engenheirada | |
| MX2025002677A (es) | Moduladores de la alfa-1 antitripsina | |
| MX2024001208A (es) | Celulas primarias geneticamente modificadas para terapia celular alogenica. | |
| UY39699A (es) | Anticuerpos anti-tau y usos de estos | |
| CL2025004118A1 (es) | Composiciones y métodos de inhibición de la adenilato ciclasa 9 (ac9). |